Ncis
Hospitals & Physicians Clinics · Singapore · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5 Lower Kent Ridge Rd, Singapore, Centra...Phone Number
+65 67737888Website
www.ncis.com.sgRevenue
$5.3 MillionIndustry
About Ncis
Ncis Org Chart
Is Ncis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Ncis has new funding data
Check out if Ncis is spiking on competitors!
Check if Ncis has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Ncis launches new products
Earning: See what the market has to say on Ncis recently announced quarterly report
Ncis, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Ncis had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Ncis
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Ncis is experiencing very low activity levels compared to other companies in the Hospitals & Physicians Clinics sector.
What does this means?
Ncis is drawing exceptional interest within the Hospitals & Physicians Clinics industry, suggesting notable developments or strong market momentum, learn more about Ncis.
Ncis Tech Stack
A closer look at the technologies used by Ncis
Ncis News & Media
SINGAPORE STRENGTHENS SARCOMA CARE THROUGH COORDINATED, MULTIDISCIPLINARY APPROACH
NCIS leads multi-institutional effort to develop expert multidisciplinary guidance to improve sarcoma diagnosis, referrals and outcomes SINGAPORE, April 11, 2026 /PRNewswire/ -- Singapore is strengthening its approach to sarcoma care, a rare group of bone and soft tissue cancers that disproportionately affect adolescents and young adults, through closer coordination across specialties and institutions, enhanced clinical guidance, and continued investment in multidisciplinary care. Adjunct AssociNational University Cancer Institute, Singapore and MiNA Therapeutics Announce Initiation of a Phase 1 Clinical Study of MTL-CEBPA in Combination With First-line Standard of Care in Advanced Liver Cancer
LONDON--(BUSINESS WIRE)--The National University Cancer Institute, Singapore (“NCIS”) and MiNA Therapeutics Limited (“MiNA” or the “Company”), the pioneer in small activating RNA therapeutics, announce that the first patient has been dosed in an investigator-sponsored Phase 1 study of MiNA’s small activating RNA oligonucleotide, MTL-CEBPA, in combination with first-line standard of care, atezolizumab and bevacizumab, in patients with previously untreated, advanced hepatocellular carcinoma (HCC)Adagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Small Cell Lung Cancer in Singapore
- Phase 1b/2 trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in Collaboration with the Singapore Translational Cancer Consortium -
Top Hospitals & Physicians Clinics Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Ncis
The National University Cancer Institute, Singapore is the only national specialist center in Singapore that provides treatment for both pediatric and adult cancers within a single facility. It offers a wide range of services including specialized programs, cancer rehabilitation, and patient support groups, catering to both local and international... Read More